

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: CV01148KB		SERIAL NO.: 10/777,849	
FORM PTO-1449				APPLICANT: Chackalamannil et al.			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: 02/12/2004		GROUP: 1624	
(Use several sheets if necessary)							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AB	5,250,534	10/05/1993	Bell et al.	514	258	
	AC	5,256,768	10/26/1993	Coughlin	530	327	
	AD	5,321,029	08/14/1994	Maschler et al.	514	263.36	
	AE	5,346,901	09/13/1994	Bell et al.	514	258	
	AF	5,393,755	02/28/1995	Neustadt et al.	514	233.2	
	AG	5,409,934	04/25/1995	Smith et al.	514	263.33	
	AH	5,470,579	11/28/1995	Bonte et al.	424	450	
	AI	5,637,693	06/10/1997	Porter et al.	514	227	
	AJ	5,688,768	11/18/1997	Coughlin et al.	514	15	
	AK	5,719,283	02/17/1998	Bell et al.	544	262	
	AL	5,769,994	06/02/1998	Coughlin et al.	514	9	
	AM	5,798,248	08/25/1998	Coughlin et al.	435	214	
	AN	5,824,683	10/20/1998	McKittrick et al.	514	257	
	AO	5,856,448	01/05/1999	Coughlin	530	388.22	
	AP	5,859,008	01/12/1999	Daugan	514	249	
	AQ	5,874,437	02/23/1999	Garvey et al.	514	258	
	AR	5,877,216	03/02/1999	Place et al.	514	573	
	AS	5,939,419	08/17/1999	Tulshian et al.	514	257	
	AT	5,955,611	09/21/1999	Dunn et al.	544	262	
	AU	5,958,926	09/28/1999	Garvey et al.	514	253	
	AV	5,981,527	11/09/1999	Daugan et al.	514	250	
	AW	5,981,583	11/09/1999	Lowrey, Fred	514	450	
	AX	6,023,640	02/08/2000	Ross, Jesse	607	2	
	AY	6,024,936	02/15/2000	Coughlin et al.	424	1.49	
	AZ	6,025,494	02/15/2000	Daugan	546	64	
	BA	6,037,346	03/14/2000	Doherty, Jr. et al.	514	258	
	BB	6,051,594	04/18/2000	Lowrey, Fred	514	450	
	BC	6,066,735	05/23/2000	Dunn et al.	544	321	
	BD	6,087,382	07/11/2000	El-Rashidy, Ragab	514	252.16	
	BE	6,100,270	08/08/2000	Campbell	514	268	
	BF	6,124,101	09/26/2000	Coughlin	435	7.1	
	BG	6,140,329	10/31/2000	Daugan	514	250	
	BH	6,143,748	11/07/2000	Daugan et al.	514	249	
	BI	6,197,541 B1	03/08/2001	Coughlin	435	69.1	
	BJ	6,362,178 B1	03/26/2002	Niewöhner et al.	514	218	
	BK	6,403,597 B1	08/11/2002	Wilson et al.	514	256	
	BL	6,469,012 B1	10/22/2002	Ellis et al.	514	258	
	BM	6,469,016 B1	10/22/2002	Place et al.	514	282	
	BN	6,472,434 B1	10/29/2002	Place et al.	514	573	
	BO	6,512,002 B2	01/28/2003	Lee et al.	514	427	

FOREIGN PATENT DOCUMENTS								
	CA CB	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
8/04	CC	EP 0 258 191 A1	02.03.88	EPO				
	CD	EP 0 389 282 A2	26.09.90	EPO				
	CE	EP 0 463 756 A1	02.01.92	EPO				
	CF	EP 0 389 282 A2	26.09.90	EPO				
	CG	EP 0 389 282 A3	26.09.90	EPO				
	CH	EP 0 389 282 B1	26.09.90	EPO				
	CI	0 389 282 A2	26.09.90	EPO				
	CJ	0 463 756 B1	02.01.92	EPO				
	CK	0 528 004 A1	03.02.93	EPO				
	CL	0 702 565 B1	27.03.96	EPO				
	CM	WO 92/11260	07.1892	PCT				
	CN	WO 91/19717	26.12.91	PCT				
	CO	WO 91/07945	13.06.91	PCT (In French)			X	
	CP	WO 91/07945 A1	13.06.91	PCT (English Translation)				
	CQ	WO 92/05176	02.04.92	PCT				
	CR	WO 92/11260	09.07.92	PCT				
	CS	WO 93/23401	25.11.93	PCT				
	CT	P 19 38 018.6	28.01.71	Germany				
	CU	WO 94/28902	22.12.94	PCT				
	CV	WO 99/54331	02.04.92	PCT (In German)			X	
	CW	WO 99/54331	28.10.99	PCT (English Translation)				
	CX	WO 92/05175	02.04.92	PCT				
	CY	WO 99/62905	09.12.98	PCT				
	CZ	WO 99/24433	20.05.99	PCT				
	DA	FR 2.116.302	13.07.72	France				
	DB	89/10123	02.11.89	WIPO				
	DC	91/19717	26.12.91	WIPO				
	DD	92/05175	02.04.92	WIPO				
	DE	92/05176	02.04.92	WIPO				
	DF	93/23401	25.11.93	WIPO				
	DG	94/19351	01.09.94	WIPO				
	DH	96/16644	06.06.96	WIPO				
	DI	96/16657	06.06.96	WIPO				
	DJ	96/32379	17.10.96	WIPO				
	DK	97/03985	06.02.97	WIPO				
	DL	97/24334	10.07.97	WIPO				
	DM	97/43287	20.11.97	WIPO				
	DN	98/08848	05.03.98	WIPO				
	DO	98/15530	16.4.98	WIPO				
	DP	98/38168	03.09.98	WIPO				
	DQ	98/49166	06.11.98	WIPO				
	DR	99/00369	07/01/99	WIPO				
	DS	99/00373	07/01/99	WIPO				
	DT	99/21558	06.05.99	WIPO				
	DU	99/21831	06.05.99	WIPO				
	DV	99/42452	26.08.99	WIPO				
	DW	99/43674	02.09.99	WIPO				
	DX	99/43679	02.09.99	WIPO				
	DY	99/64333	26.10.99	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
EA	Ho-Sam Ahn et al, "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity", <i>J. Med. Chem.</i> , Vol. 40, No. 14, pp. 2196-2210 (1997).
EB	J.L. Ambrus et al, "Studies on Vasoocclusive Crisis of Sickle Cell Disease. I. Effect of Pentoxifylline", <i>Journal of Medicine</i> , Vol. 10, No. 6, pp. 445-458 (1979).
EC	Bradley D. Anderson et al, "Preparation of Water-Soluble Compounds Through Salt Formation", <i>The Practice of Medicinal Chemistry</i> , C. G. Wernuth, Ed., Academic Press, New York, pp. 739-754 (1998).
ED	M.I. Argal et al, "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein Kinase Activity and Cyclic Nucleotide Levels", <i>J. Mol. Cell Cardiol</i> , Vol. 12, No. 10, pp. 939-954, Abstract (1980).
EE	Hans-Joachim Arnold et al, "Pharmacopoeia of Traditional Medicine in Venda", <i>Journal of Ethnopharmacology</i> , Vol. 12, pp. 35-74 (1984).
EF	William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", <i>The Journal of Urology</i> , Vol. 145, No. 4, p. 341A, Abstract No. 516 (1991).
EG	Joseph A. Beavo, "Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms", <i>Physiological Reviews</i> , Vol. 75, No. 6, pp. 725-748 (October 1995).
EH	Joseph A. Beavo & David H. Reifanyder, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", <i>Trends in Pharmacological Sciences</i> , Vol. 11, No. 4, pp. 150-155 (April 1990).
EI	Stephen M. Berge et al, "Pharmaceutical Salts", <i>J. of Pharmaceutical Sciences</i> , Am. Pharm. Assoc. and Pergamon Press, Vol. 66, No. 1, pp. 1-19 (January, 1977).
EJ	Anne Bowman et al, "Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle", <i>Br. J. Pharmacol.</i> , Vol. 81, pp. 665-674 (1984).
EK	V. Mirone et al, letter to ed. re. "Intracavernous Cyclic GMP Products Produces Penile Erection in Patients with Erectile Dysfunction", <i>British Journal of Urology</i> , Vol. 71, No. 3, p. 365 (March 1993).
EL	Gary Brooker et al, "Radioimmunoassay of Cyclic AMP and Cyclic GMP", <i>Advances in Cyclic Nucleotide Research</i> , Paul Greengard et al, Eds., Vol. 10, pp. 1-33 (1979).
EM	Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of corpus cavernosum smooth muscle", <i>Ph.D. dissertation U.C.L.A.</i> (UMI Dissertation Services Order No. 9319914) (179 pgs) (1993).
EN	Peggy Bush et al, "Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum", <i>Journal of Urology</i> , Vol. 147, pp. 1650-1655 (June 1992).
EO	S. Carrier et al, "Erectile Dysfunction", <i>Endocrinology and Metabolism Clinics of North America: Clinical Andrology</i> , Vol. 23, No. 4, pp. 773-782 (Dec. 1994).
EP	P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3-Methylflavone-8-carboxylic Acid", <i>Drug. Res.</i> , Vol. 38 (I), No. 3, pp. 379-382 (1988).
EQ	J. Cortijo et al, "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including Studies with Human Bronchus", <i>Br. J. Pharmacol.</i> , Vol. 108, pp. 562-568 (1993).
ER	Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors", <i>Br. J. Pharmacol.</i> , Vol. 106, pp. 1028-1034 (1992).
ES	Dario Doller et al, "The GIF System as a Tool in Medicinal Chemistry: The Oxidation of SCH57726 under GOAGG III Conditions", <i>Bioorganic and Medicinal Chemistry Letters</i> , Vol. 7, No. 11, pp. 1381-6 (1997).
ET	Dukarm R.C., et al., (1999) The cGMP-specific Phosphodiesterase Inhibitor E4021 Dilates the Pulmonary Circulation. <i>American Journal Respir. Crit. Care Med.</i> , Volume 160:858-865.
EU	I.J. Fishman, "Treating Erectile Dysfunction: New Approaches", <i>Drug Therapy</i> , Vol. 8, pp. 102-110 (August 1989).
EV	Gaine S.P., et al., (1998) Primary Pulmonary Hypertension, <i>The Lancet</i> , Volume 352:719-725.
EW	P.G. Gillespie & J.A. Beavo, "Inhibition and Stimulation of Photoreceptor Phosphodiesterases by Dipyrindamole and M & B 22,948", <i>Molecular Pharmacology</i> , Vol. 36, pp. 773-781 (Nov. 1988).
EX	J.C. Gingell, et al, "Emerging pharmacological therapies for erectile dysfunction", <i>Exp. Opin. Ther. Patents</i> , Vol. 9, No. 12, pp. 1689-1696 (1999).
EY	Philip L. Gould, "Salt Selection for Basic Drugs", <i>Int'l J. of Pharmaceutics</i> , Elsevier, Vol. 33, pp. 201-217 (1986).
EZ	Theodora W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, pp. 1-9 (1981).
FA	Alain Gregoire, "Viagra: on release", <i>BMJ</i> , Vol. 317, p. 759-760 (Sept. 19, 1998).

80	FB	Hanasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Pulmonary Hypertension in Rats, <i>American Journal of Physiol.</i> , Volume 277 (Lung Cell. Mol. Physiol. 21): L225-L232.
	FC	"Pharmaceutical Coloring Agents", <i>Handbook of Pharmaceutical Excipients</i> , American Pharmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1986).
	FD	Takeru Higuchi, "Prodrug & Drug Delivery - An Overview", <i>Bioreversible Carriers in Drug Design: Theory and Application</i> , Edward B. Roche, Ed., Pergamon Press, New York, pp. 1-12 (1987).
	FE	T. Higuchi et al, Eds., "Pro-drugs as Novel Drug Delivery Systems", <i>ACS Symposium Series 14</i> , American Chemical Society, Wash., D.C., pp. 1-115 (1975).
	FF	F. Holmquist et al, "Actions of 3-Morpholinomethyl-5-nitro-1H-benzotriazole (SIN-1) on Rabbit Isolated Penile Erectile Tissue", <i>Journal of Urology</i> , Vol. 150, No. 4, pp. 1310-1315 (Oct. 1993).
	FG	F. Holmquist et al, "Effects of the nitric oxide synthase inhibitor N <sup>G</sup> -nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit", <i>Acta Physiol Scand</i> , Vol. 143, pp. 299-304 (1991).
	FH	Sue Ellen Jackson et al, "Erectile Dysfunction: Therapy Health Outcomes", <i>Outcomes Research</i> , Pfizer, Inc., Elsevier (Dec. 16, 1997).
	FI	T. Katsushima et al., Structure-Activity Relationships of 8-Cycloalkyl-1,3-dipropylxanthines as Antagonists of Adenosine Receptors, <i>J. Med. Chem.</i> , 1990, 33, pp. 1906-1910.
	FJ	Yasuo Kawanishi et al, "Double-Blind Trial of Oral Prostaglandin E <sub>1</sub> on Impotence", <i>The Japanese Urological Association</i> , Vol. 83, No. 1, Abstract, pp. 1656-1661 (Oct. 1992).
	FK	Stanley G. Korenman et al, "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," <i>J. Am. Geriatrics Soc.</i> , Vol. 41, No. 4, pp. 363-366 (April, 1993).
	FL	Robert J. Krane et al, "Impotence", <i>New England Journal of Medicine</i> , Vol. 321, No. 24, pp. 1648-1658 (Dec. 14, 1989).
	FM	Kremzer, et al., "Synth. & Biol. activity of diprophylline anal.", <i>Khim-Farm. Zh.</i> , 15/6, 59-64 (1981); CAS ABS '81:532818.
	FN	W.R. Kukovetz et al, "Evidence for Cyclic GMP-Mediated Relaxant Effects of Nitro-Compounds in Coronary Smooth Muscle", <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , Vol. 310, pp. 129-138 (1979).
	FO	Y.-M. Lin et al, "The rabbit as an intracavernous injection study model", <i>Urol. Res</i> , Vol. 24, pp. 27-32 (1996).
	FP	Tom F. Lue, "Topical and Oral Agents for Erectile Dysfunction", <i>J. Formos Med. Assoc</i> , Vol. 98, No. 4, pp. 233-241 (March 9, 1999).
	FQ	James A. Lugg et al, "The Role of Nitric Oxide in Erectile Function," <i>J. of Andrology</i> , Vol. 16, No. 1, pp. 2-4 (Jan./Feb. 1995).
	FR	E.G. McMahon et al, "Depressor and Natriuretic Effects of M & B 22,948, a Guanosine Cyclic 3',5'-Monophosphate-Selective Phosphodiesterase Inhibitor", <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 2513, pp. 1000-1005 (1989).
	FS	W. Meinhardt et al, "The influence of medication on erectile function", <i>International Journal of Impotence Research</i> , Vol. 9, pp. 17-26 (1997).
	FT	M.F. Meyer et al, "Intracavernous Application of SIN-1 in Rabbit and Man: Functional and Toxicological Results", <i>Ann. Urol.</i> , Vol. 27, No. 3, pp. 179-182 (1993).
	FU	Alvaro Morales et al, "Oral and Topical Treatment of Erectile Dysfunction", <i>Urologic Clinics of North America</i> , Vol. 22, No. 4, pp. 879-886 (Nov. 1995).
	FV	John E. Morley, "Management of Impotence, Diagnostic considerations and therapeutic options", <i>Impotence</i> , Vol. 93, No. 3, pp. 65-67, 71-72 (Feb. 16, 1993).
	FW	Murray, K.J., Phosphodiesterase V <sub>A</sub> Inhibitors, <i>DN&amp;P 6(3)</i> , pp. 150-155, April 1993.
	FX	C. David Nicholson et al, "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", <i>Trends in Pharmacological Sciences</i> , Vol. 12, pp. 19-27 (Jan. 1991).
	FY	Nantka-Namirski, P., et al., Synteza 7-Podstawionych Pochodnych 8-aminometylo-1,3-Dwumetloksantyny, <i>ACIA POLAN, PHARM, XXX1 Nr 1</i> , (1974) [in Polish]
	FZ	Nantka-Namirski, P., et al., Synthesis of 7-Substituted Derivates of 8-aminomethyl-1,3-dimethylxanthine, <i>Acta Polon. Pharma</i> , 31(1):5-11 (1974) [English Translation]
	GA	Ohnishi M., et al., (1999) E4021, a Selective Phosphodiesterase 5 Inhibitor, Potentiates the Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. <i>Journal of Cardiovascular Pharmacology</i> , Volume 33:619-624.
	GB	Elizabeth Palmer, "Making the love drug", <i>Chemistry in Britain</i> , Vol. 35, No. 1, pp. 24-26 (Jan. 1999)
	GC	Pfizer, "Erectile Dysfunction", 1998 Annual Report, p. 21.
	GD	Physicians' Desk Reference, Medical Economics Company, 56 <sup>th</sup> Ed., pp. 2534-37 (2001)
	GE	Physician's Desk Reference, Medical Economics Company, 46 <sup>th</sup> Ed., pp. 1099-1100 (1992).
	GF	Physician's Desk Reference, Medical Economics Company, 48 <sup>th</sup> Ed., Product Identification Dayton Himblin Tablets and Yohimex Tablets, pp. 409, 905 & 1190 (1992)

GG	Jacob Rajfer et al, "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavemosum in Response to Nonadrenergic, Noncholinergic Neurotransmission", <i>New England Journal of Medicine</i> , Vol. 326, No. 2, pp. 90-94 (Jan. 9, 1992)
GH	J. Reiser et al, "The Effect of Zaprinst (M&B 22, 948, an Orally Absorbed Mast Cell Stabilizer) on Exercise-Induced Asthma in Children", <i>Br. J. Dis. Chest.</i> , Vol. 80, pp. 157-163 (1986)
GI	Remington's Pharmaceutical Sciences, "Coloring, Flavoring and Diluting Agents", 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1288-1300 (1990)
GJ	Remington's Pharmaceutical Sciences, 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1519-1712 (1990)
GK	Alan Riley, "Oral Treatments for Erectile Dysfunction", <i>International Journal of STD &amp; AIDS</i> , Vol. 7, Suppl 3, pp. 16-18 (1996)
GL	N.I. Romanenko et al, "Synthesis and biological activity of 3-methyl, 7- or 8-alkyl-, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines", <i>Chemical Abstracts</i> , 106: 95577n (1986)
GM	Raymond C. Rosen et al, "The process of care model for evaluation and treatment of erectile dysfunction", <i>International Journal of Impotence Research</i> , Vol. 11, pp. 59-74 (1999)
GN	David P. Rotella et al, "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction", <i>J. Med. Chem.</i> , Vol. 43, No. 7, pp. 1257-1263 (2000)
GO	Robin M. Rudd et al, "Inhibition of Exercise-Induced Asthma by an Orally Absorbed Mast Cell Stabilizer (M & B 22,948)", <i>Br. J. Dis. Chest</i> , Vol. 77, pp. 78-84 (1983)
GP	Richard Sachse et al, "Safety, Tolerability and Pharmacokinetics of Bay 38-9456 in Patients with Erectile Dysfunction", <i>Journal of Urology</i> , Vol. 163, No. 4, p. 204 (May 2000)
GQ	T. Saeki & I. Saito, "Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes from Pig Aorta", <i>Biochemical Pharmacology</i> , Vol. 48, No. 5, pp. 833-839 (1993)
GR	Junichi Shimada et al, "A Convenient Synthesis of Tricyclic Purine Derivatives", <i>J. of Heterocyclic Chemistry</i> , Vol. 30, pp. 241-248, (1993)
GS	Christian G. Stief et al, "Preliminary Results with the Nitric Oxide Donor Linsidomine Chlorhydrate in the Treatment of Human Erectile Dysfunction", <i>The Journal of Urology</i> , Vol. 148, No. 5, pp. 1437-1440 (Nov. 1992)
GT	Christian G. Stief et al, "Preliminary report on the effect of the nitric oxide donor SIN-1 on human cavernous tissue in vivo", <i>World J. Urol</i> , Vol. 9, pp. 237-239 (1991)
GU	Christian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) Inhibitors on Human and Rabbit Cavernous Tissue in Vitro and in Vivo", <i>J. of Urology</i> , Am. Urological Assoc., Vol. 159, pp. 1390-1393 (1998)
GV	A. Taher et al, "Phosphodiesterase Activity in Human Cavernous Tissue and the Effect of Various Selective Inhibitors", <i>The Journal of Urology</i> , Vol. 149, No. 4, p. 285 (Abstract) (April 1993)
GW	A. Taher et al, "Cyclic Nucleotide Phosphodiesterase Activity in Human Cavernous Smooth Muscle and the Effect of Various Selective Inhibitors", <i>Int. J. Impotence Res.</i> , Vol. 4, Suppl. 2, p.11 (1992)
GX	Yoneda, F. et al, A New Synthesis of Substituted 8-Aminopurine Derivatives, <i>Bulletine of the Chemical Society of Japan</i> , Vol. 46, pp. 1836-1839 (1973).
GY	Yoshiatsu Takahashi et al, "Pharmacological Effects of Adenosine on Canine Penile Erection", <i>Tohoku J. Exp. Med.</i> , Vol. 165, pp. 49-58 (1991)
GZ	Youssef, S. et al., <i>Purines XIV. [1] Reactivity of 8-Bromo-3,9-dimethylxanthine Towards Some Nucleophilic Reagents</i> , <i>J. Heterocyclic Chem.</i> , 35, 949 (1998).
HA	Harvey C. Taub et al, "Relationship between Contraction and Relaxation in Human and Rabbit Corpus Cavemosum", <i>Urology</i> , Vol. 42, No. 6, pp. 698-704 (Dec. 1993)
HB	W. Joseph Thompson, "Cyclic Nucleotide Phosphodiesterases: Pharmacology, Biochemistry and Function", <i>Pharmac. Ther.</i> , Vol. 51, pp. 13-33 (1991)
HC	Flavio Trigo-Rocha et al, "The Role of Cyclic Adenosine Monophosphate, Cyclic Guanosine Monophosphate, Endothelium and Nonadrenergic, Noncholinergic Neurotransmission in Canine Penile Erection", <i>Journal of Urology</i> , Vol. 149, No. 4, pp. 872-877 (April 1993)
HD	Flavio Trigo-Rocha et al, "Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs", <i>Am. J. Physiol.</i> , Vol. 264, pp. H419-H422 (1993)
HE	Flavio Trigo-Rocha et al, "Intracellular Mechanism of Penile Erection in Monkeys", <i>Neurology and Urodynamics</i> , Vol. 13, pp. 71-80 (1994)
HF	Flavio Trigo-Rocha et al, "The Effect of Intracavernous Injection of Potassium Channel Openers in Monkeys and Dogs", <i>Int. J. of Impotence Research</i> , Smith-Gordon, London, Vol. 7, pp. 41-48 (1995)
HG	Flavio Trigo-Rocha et al, "Sodium Nitroprusside: Physiologic Effects as a Nitric Oxide Donor in Three Species", <i>Int. J. of Impotence Research</i> , Smith-Gordon, London, Vol. 7, pp. 49-56 (1995)
HH	Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Diagnosis and Treatment of Erectile Dysfunction", <i>Urology</i> , Vol. 44, No. 4, pp. 553-556 (Oct. 1994)

